Compare Fabrinet (FN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Summit Therapeutics Inc — how do they compare? Fabrinet trades at $491.34 (market cap $17.46B), while Summit Therapeutics Inc trades at $17.42 (market cap $13.71B). The key difference: Fabrinet is the larger of the two by market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 1,199,886). Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Summit Therapeutics Inc for 16 Days on average.
| FN | SMMT | |
|---|---|---|
Market Cap | $17.46B | $13.71B |
Volume | 1,199,886 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $746.47 | $26.38 |
52-Week Low | $361.94 | $12.43 |
Typical Hold Time | 30 Days | 16 Days |
Enterprise Value | $16.59B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $486.8, down 2.25% on the day, amid a mixed technical picture with a bullish moving average signal but overbought RSI levels. Fundamentally, the company shows strong growth with Q2 2026 EPS of $4.10 beating expectations, revenue projected to rise to $4.6B in 2026, and robust profitability metrics including a 21.33% ROE. Recent news highlights surging AI data center demand driving expansion.
The outlook is positive given analyst consensus of a $769.50 price target and 75% buy ratings, though risks include customer concentration and high capital expenditures impacting cash flow. The stock offers exposure to AI infrastructure growth but requires monitoring of execution and competitive pressures.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
